XXXX administration protects @entity63 -reperfusion injury in isolated @entity95 lungs.

@entity7955 @entity63 @entity7954 @entity4613 @entity95 @entity651 @entity2388
UNASSIGNED: @entity7954 ( @entity7955 ) is an intermediate metabolite of the glycolytic pathway and an in vivo high-energy @entity4613 compound. We have examined the protective effects of @entity7955 on @entity63 -reperfusion @entity651 in isolated @entity95 lungs perfused with a physiological salt solution. The lungs were divided into three treatment groups: (1) @entity63 -reperfusion (IR), (2) @entity63 -reperfusion with @entity7955 treatment ( @entity7955 -IR), in which 1 mM @entity7955 was pre-administered into the perfusate during the stable period, and (3) ventilation-perfusion continued without interruption (Cont). In the IR and @entity7955 -IR groups, ventilation-perfusion was discontinued for about 60  min after a 30-min stable period and then restarted. The capillary filtration coefficients (K fc) and @entity2388 concentration in the perfusate were determined immediately before @entity63 and 30 and 60  min after reperfusion. The left lungs were dried at the end of the experiment to calculate the tissue wet-to-dry weight ratio (W/D). The K fc values after reperfusion were significantly higher in the IR group than in the other two groups. @entity2388 concentrations were significantly higher at three time-points in the @entity7955 -IR group than in the other two groups. The W/D was significantly higher in the IR group than in the other two groups. Based on these results, we conclude that the administration of @entity7955 prior to @entity63 alleviates @entity63 -reperfusion injury.
